Blocking Piezo2 may treat pulmonary fibrotic diseases

Researchers have discovered a new approach to treating lung fibrosis by targeting a receptor known as Piezo2. This receptor senses mechanical forces in tissues, which are essential in the development of fibrotic diseases. The study published in The American Journal of Pathology details how Piezo2 plays a significant role in pulmonary fibrosis, a condition that severely affects lung function. Idiopathic pulmonary fibrosis (IPF) is one of the most serious forms, with patients typically surviving about 2.9 years after diagnosis. In their research, scientists examined lung tissues from IPF patients, mouse models, and lung cell cultures. They found high levels of Piezo2 in both human and mouse lung tissues, as well as in cells responsible for creating fibrosis. The study also showed that when lung fibroblasts were placed on stiffer surfaces, they became more active in creating fibrotic tissue. By inhibiting Piezo2, either through silencing its RNA or using a peptide inhibitor, researchers were able to reduce the profibrotic activity of these cells. Lead investigator Patricia J. Sime believes this could lead to new therapies for lung fibrosis, an area with a critical need for better treatment options. Current therapies like nintedanib and pirfenidone can slow but not stop the progression of pulmonary fibrosis, which can be difficult to treat due to complex disease pathways. Margaret A.T. Freeberg, the first author of the study, emphasized the challenge of treating IPF and discussed the potential of Piezo2 as a new target for therapy. The researchers are optimistic that targeting Piezo2 could help slow the progression of pulmonary fibrosis, either alone or in combination with existing treatments. This research could pave the way for new drugs and attract interest from pharmaceutical companies.